A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom

References

• Lepine JP, Briley M. The increasing burden of depression. Neuropsychiatr Dis Treat. 2011;7(1):3–7.
   PubMedGoogle Scholar
• McManus SBP, Jenkins R, Brugha T, editors. Mental health and wellbeing in England: adult psychiatric morbidity survey 2014. Leeds (UK): NHS Digital; 2016.
   Google Scholar
• Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9:90.
   PubMed Web of Science ®Google Scholar
• NICE. National Institute for Health and Care Excellence: Clinical Guidelines. Depression in adults: recognition and management. London: National Institute for Health and Care Excellence (UK); 2009.
   Google Scholar
• Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29(5):459–525.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Fusco A, Anastasia A, et al. Brexpiprazole for treatment-resistant major depressive disorder. Expert Opin Pharmacother. 2019;20(16):1925–1933.
   PubMed Web of Science ®Google Scholar
• Ruberto VL, Jha MK, Murrough JW. Pharmacological treatments for patients with treatment-resistant depression. Pharmaceuticals (Basel). 2020;13(6):116.
   PubMedGoogle Scholar
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–1366.
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ comparative effectiveness reviews. second-generation antidepressants in the pharmacologic treatment of adult depression: an update of the 2007 comparative effectiveness review. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011.
   Google Scholar
• EMA. Guideline on clinical investigation of medicinal products in the treatment of depression. European Medicines Agency; 2013.
   Google Scholar
• Sussman M, O’sullivan AK, Shah A, et al. Economic burden of treatment-resistant depression on the U.S. Health Care System. JMCP. 2019;25(7):823–835.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. AJP. 2006;163(11):1905–1917.
   Web of Science ®Google Scholar
• McCrone P, Rost F, Koeser L, et al. The economic cost of treatment-resistant depression in patients referred to a specialist service. J Ment Health. 2018;27(6):567–573.
   PubMed Web of Science ®Google Scholar
• Mrazek DA, Hornberger JC, Altar CA, et al. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013. Psychiatr Serv. 2014;65(8):977–987.
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Li Z, McKendrick J. Selective serotonin reuptake inhibitor treatment in the UK: risk of relapse or recurrence of depression. Br J Psychiatry. 2000;177:163–168.
   PubMed Web of Science ®Google Scholar
• Garcia-Toro M, Medina E, Galan JL, et al. Treatment patterns in major depressive disorder after an inadequate response to first-line antidepressant treatment. BMC Psychiatry. 2012;12:143.
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Maurino J, Cordero L, et al. Assessment of pharmacological strategies for management of major depressive disorder and their costs after an inadequate response to first-line antidepressant treatment in primary care. Ann Gen Psychiatry. 2012;11(1):22.
   PubMedGoogle Scholar
• Jaffe DH, Rive B, Denee TR. The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study. BMC Psychiatry. 2019;19(1):247.
   PubMed Web of Science ®Google Scholar
• Schultz J, Joish V. Costs associated with changes in antidepressant treatment in a managed care population with major depressive disorder. Psychiatr Serv. 2009;60(12):1604–1611.
   PubMed Web of Science ®Google Scholar
• Sheffield RE, Lo Sasso AT, Young CH, et al. Selective serotonin reuptake inhibitor usage patterns as risk factors for hospitalization. Adm Policy Ment Health. 2002;30(2):121–139.
   PubMedGoogle Scholar
• Johnston KM, Powell LC, Anderson IM, et al. The burden of treatment-resistant depression: a systematic review of the economic and quality of life literature. J Affect Disord. 2019;242:195–210.
   PubMed Web of Science ®Google Scholar
• NICE. British national formulary. London (UK): BMJ Group; 2019.
   Google Scholar
• Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry. 2007;52(1):46–54.
   PubMed Web of Science ®Google Scholar
• Marsden J, White M, Annand F, et al. Medicines associated with dependence or withdrawal: a mixed-methods public health review and national database study in England. Lancet Psychiatry. 2019;6(11):935–950.
   PubMed Web of Science ®Google Scholar
• Gibson TB, Jing Y, Smith Carls G, et al. Cost burden of treatment resistance in patients with depression. Am J Manag Care. 2010;16(5):370–377.
   PubMed Web of Science ®Google Scholar
• Feldman RL, Dunner DL, Muller JS, et al. Medicare patient experience with vagus nerve stimulation for treatment-resistant depression. J Med Econ. 2013;16(1):62–74.
   PubMedGoogle Scholar
• Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019;76(9):893.
   PubMed Web of Science ®Google Scholar
• Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616–630.
   PubMed Web of Science ®Google Scholar
• Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6):428–438.
   PubMed Web of Science ®Google Scholar
• Curtis L, Burns A. Unit costs of health and social care 2017. Canterbury (UK): Personal Social Services Research Unit, University of Kent; 2017.
   Google Scholar
• McLoughlin D, Mogg A, Eranti S, et al. The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: a multicentre pragmatic randomised controlled trial and economic analysis. Health Technol Assess. 2007;11(24):1–54.
   PubMed Web of Science ®Google Scholar
• Nightingale Hospital. Outpatient therapy fees. 2017. [cited 2018 Feb 20]. Available from: https://www.nightingalehospital.co.uk/wp-content/uploads/Nightingale-Hospital-Outpatient-Patients-Fees-2018.pdf.
   Google Scholar
• Curtis L. Unit costs of health and social care 2010. Canterbury (UK): Personal Social Services Research Unit, University of Kent; 2010.
   Google Scholar
• Kibble S, Gray D, Prat-Sala M, et al. Recovery coaching in an acute older people rehabilitation ward. BMJ Qual Improv Rep. 2014;3(1):u205646.w2316.
   PubMedGoogle Scholar
• Rayner L, Hotopf M, Petkova H, et al. Depression in patients with chronic pain attending a specialised pain treatment centre: prevalence and impact on health care costs. Pain. 2016;157(7):1472–1479.
   PubMed Web of Science ®Google Scholar
• Department of Health & Social Care. NHS reference costs 2016–2017. [cited 2018 Feb 20]. Available from: https://improvement.nhs.uk/documents/6467/201617_ReferenceCostData.zip.
   Google Scholar